DeLLphi-305 Archives - PharmaDeviceNews

A representative image illustrating BlossomHill Therapeutics’ BH-30643 lung cancer program as the FDA grants Fast Track designation for the investigational therapy targeting EGFR C797S-positive non-small cell lung cancer after resistance to third-generation EGFR inhibitors.

AstraZeneca and Amgen report 58% lower death risk with IMFINZI and tarlatamab in small-cell lung cancer

by Pallavi Madhiraju
October 25, 2026
0 Comments

AstraZeneca PLC (NASDAQ: AZN) and Amgen Inc. (NASDAQ: AMGN) have reported Phase 3 findings showing that IMFINZI (durvalumab) combined with IMDELLTRA (tarlatamab-dlle) reduced the hazard of death by 58% compared with IMFINZI alone as first-line maintenance treatment for extensive-stage small-cell lung cancer. Presented at the European Society for Medical Oncology Congress 2026 on October 24

Amgen is seeking to move Imdelltra earlier in small cell lung cancer while reducing the practical monitoring burden associated with treatment. Representative image.

Pharma & Biotech

Amgen removes an Imdelltra treatment burden just as its DLL3 therapy approaches a much larger first-line opportunity

by Pallavi Madhiraju
September 17, 2026
0 Comments

The FDA has reduced monitoring requirements around the first two Imdelltra doses, lowering an important logistical burden days after Amgen reported positive Phase 3 survival data in first-line extensive-stage small cell lung cancer.

Pharma & Biotech

Only about 40% of extensive-stage SCLC patients reach second-line therapy. Amgen and AstraZeneca are moving Imdelltra earlier

by Pallavi Madhiraju
September 11, 2026
0 Comments

Amgen’s Phase 3 DeLLphi-305 trial met its primary overall survival endpoint with Imdelltra plus Imfinzi as first-line maintenance in extensive-stage small cell lung cancer.